Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Forest Labs Will Acquire Furiex
by Ann M. Thayer
May 5, 2014
| A version of this story appeared in
Volume 92, Issue 18
Forest Laboratories will pay up to $1.5 billion to purchase Furiex Pharmaceuticals of Morrisville, N.C. Furiex expects to apply soon for FDA approval for its lead product, eluxadoline, a treatment for irritable bowel syndrome. Forest has agreed to sell Furiex’s royalties on two other drugs to Royalty Pharma for $415 million, provided the deal goes through. Forest expanded its gastroenterology business earlier this year by acquiring the specialty pharma firm Aptalis for $2.9 billion. Meanwhile, the generic drug maker Actavis is in the process of acquiring Forest for $25 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X